How much do blood-based biomarkers help in diagnosing Alzheimer’s disease? Quite a lot, according to scientists led by Albert Puig Pijoan and Marc Suárez-Calvet at the Hospital del Mar in Barcelona, ...

Two groups of scientists have found that the same protein can have opposing effects on α-synuclein pathology. Microglia eliminate α-synuclein from neurons by “trogocytosis.” Silencing the glycoprotein ...

Anti-amyloid immunotherapies come with a risk of serious brain hemorrhage, which can be mitigated via monitoring for amyloid-related imaging abnormalities (ARIA) via MRI scans. Early signs of edema ...

The approval of amyloid-targeted monoclonal antibodies as disease-modifying therapies was a landmark moment for the Alzheimer’s field, but risks and monitoring requirements hamper acceptance by ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

White-matter hyperintensities, a sign of damage to the brain’s vasculature, are common on MRI scans of people with Alzheimer’s disease. Do they indicate an independent vascular co-pathology, or are ...

Aβ may stimulate p-tau secretion at lipid rafts in the neuronal membrane. Plaque growth, not presence, pierces axonal membranes, releasing p-tau. Turning interneuron activity up or down modulates ...

Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...

The notion that lithium might treat Alzheimer’s was revived last year when scientists reported that the brains of people and mice with amyloid pathology are deficient in the metal ion, and that the ...

Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...